CVS Caremark Expands Zepbound and Foundayo Coverage

CVS Caremark will expand its commercial formulary to include oral and injectable obesity treatments.

Expansion of Pharmacy Benefit Formularies

On May 29, 2026, CVS Caremark announced updates to its commercial formularies that will expand coverage for anti-obesity medications. According to a CVS Health press release, the pharmacy benefit manager (PBM) intends to add Eli Lilly's new oral GLP-1 agonist, Foundayo (orforglipron), and restore preferred formulary status to Zepbound (tirzepatide). These updates come after months of discussions surrounding patient access and cost management in the weight loss sector. Fierce Pharma reported that CVS Caremark's actions represent a strategic shift as PBMs navigate the high demand and budget impacts of metabolic therapies.

The timeline for these coverage adjustments includes the following key milestones:

• June 1, 2026: Oral Foundayo is added to commercial formularies with the removal of the new-to-market block.
• July 1, 2026: Certain Medicare Part D transition program cost caps may go into effect for eligible members.
• October 1, 2026: Zepbound is restored as a preferred drug on CVS Caremark commercial formularies.

Coverage Details for Oral Foundayo

Foundayo, an oral non-peptide GLP-1 receptor agonist developed by Eli Lilly, is scheduled to join the CVS Caremark commercial formulary on June 1, 2026. According to clinical trial data published in scientific journals, orforglipron offers an oral alternative to injectable treatments, which may improve adherence for patients who prefer pills over injections. CVS Health stated that the "new-to-market" block on Foundayo will be removed, allowing coverage for eligible members under participating employer plans. Medical experts suggest that the availability of oral GLP-1 options could reduce supply chain pressures associated with injection pen manufacturing, though patients should consult their healthcare providers to discuss clinical suitability.

Restoration of Preferred Status for Zepbound

In addition to adding Foundayo, CVS Caremark plans to restore preferred status to Zepbound on its commercial formularies effective October 1, 2026. Zepbound, a dual GIP and GLP-1 receptor agonist, had previously faced coverage exclusions or non-preferred placement under certain pharmacy benefit structures. Healthcare Dive noted that restoring Zepbound as a preferred drug means patients may face lower out-of-pocket costs and fewer prior authorization hurdles, depending on their plan's design. For patients evaluating weight management treatments, this decision may expand access to various tirzepatide options currently available on the market.

Employer Opt-Ins and Coverage Variations

Although CVS Caremark is adding these medications to its standard commercial formularies, coverage is not automatic for all plan participants. Healthcare Dive reported that individual employers and plan sponsors retain ultimate discretion over whether to cover weight loss medications within their benefit designs. Consequently, the presence of Foundayo or Zepbound on the CVS Caremark preferred list does not guarantee coverage for every employee. Individuals are encouraged to check with their human resources departments or use online portal tools to check if they qualify for covered weight loss services under their specific plans.

Financial and Access Implications for Patients

According to CVS Health, eligible patients with commercial insurance may access Zepbound and Foundayo for co-pays as low as $25 per month, subject to manufacturer savings card terms and plan structures. Additionally, Managed Healthcare Executive reported that starting July 1, 2026, some Medicare Part D plan sponsors may offer cost caps through experimental transition programs, though federal coverage of obesity-only treatments remains subject to legislative guidelines. CVS Caremark confirmed that Novo Nordisk's Wegovy (semaglutide) will also remain a preferred option, ensuring that patients have multiple covered pathways for metabolic health management. Individuals should verify their specific benefit details directly with their plan administrator to determine final out-of-pocket costs.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.